Search

At Memorial Sloan Kettering Cancer Center, we have now analyzed more than 50,000 samples in our prospective cohort with MSK-IMPACT™.

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology; Grayer Family Chair at MSK, has been elected to the 10th class of Giants of Cancer Care® for his contributions in translational science.

Learn how immune cells in the lungs trigger invasive fungal cells to self-destruct. The discovery could produce therapies to prevent infection in cancer patients.

Learn how Memorial Sloan Kettering Cancer Center kept caring for patients during the response to COVID-19, and how lessons learned during the pandemic are helping cancer care.

Hear from five Fred’s Team members about why they’re running the New York City Marathon in 2017.

Read how genetic differences affect levels of Epstein Barr Virus in the body and the risk of certain chronic diseases.

Mysterious circular DNA may contribute to neuroblastoma and other childhood cancers.

Updated survival outcomes from the EMBER-3 trial reinforced the clinical benefit of imlunestrant-based regimens as all-oral, chemotherapy-free treatment options for endocrine-pretreated patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. Breast medical oncologist Komal Jhaveri, MD, FACP, presented the latest results for the trial at SABCS, and was also the lead and corresponding author of the paper published simultaneously in the Annals of Oncology.